for use in patients with advanced or recurrent endometrial cancer who have tumors that are mismatch repair–deficient .
"There was also an early trend toward improved overall survival in all populations," noted lead author Mansoor R. Mirza, MD, chief oncologist at the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark. Overall survival also favored dostarlimab, although Mirza cautioned that it was only mature for 33% of the population. But at 24 months, overall survival was 71.3% vs 56.0% among placebo recipients .
"The safety profile for dostarlimab and chemotherapy was manageable and generally consistent with that of the individual drugs," said Mirza.Endometrial cancer is one of the few types of cancer with a rising incidence and mortality, and it is projected to be the third most prevalent cancer and the fourth leading cause of cancer death among women, noted Ramez N. Eskander, MD, associate clinical professor in Ob/Gyn & Reproductive Sciences at the University of California, San Diego.
Adverse events were as expected for pembrolizumab and combination chemotherapy, Eskander commented. Toxicity was similar in both groups. In the dMMR cohort, adverse events of any cause occurred in 98.2% of the patients in the pembrolizumab group vs 99.1% in the placebo group. In the pMMR cohort, these percentages were 93.5% vs 93.4%, respectively. In the dMMR cohort, 63.3% of the pembrolizumab group vs 47.2% of the placebo group had grade 3 or higher adverse events.
Entertainment Entertainment Latest News, Entertainment Entertainment Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: FOX26Houston - 🏆 448. / 53 Read more »